Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with amino-acid
substitutions and deletions in spike protein (S) can reduce the effectiveness of monoclonal …

Since the outbreak of the pandemic, waves of epidemics caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants that harbor novel mutations have never …

Despite an unprecedented global research effort on SARS-CoV-2, early replication events
remain poorly understood. Given the clinical importance of emergent viral variants with …

With the global outbreak of SARS-CoV-2, the inadequacies of current detection technology
for respiratory viruses have been recognized. Rapid, portable, accurate, and sensitive …

Although some COVID-19 patients maintain SARS-CoV-2-specific serum immunoglobulin G
(IgG) for more than 6 months postinfection, others eventually lose IgG levels. We assessed …

With the onset of the COVID-19 pandemic, the amount of data on genomic and proteomic
sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stored in …

One of the primary threats to the goal of controlling and eventually defeating SARS-CoV-2 is
that of mutation. Recognizing this, a great amount of effort and dedicated study is being …

SARS‐CoV‐2 continues to leave its toll on global health and the economy. Management of
the pandemic will rely heavily on the degree of adaptive immunity persistence following …

Abstract COVID‐19 convalescent plasma (CCP) was among the few frontline therapies used
to treat COVID‐19. After large randomized controlled trials (RCTs) relying on late use in …

Patients with haematological malignancies are more likely to have poor responses to
vaccination. Here we provide detailed analysis of the humoral and cellular responses to …